PB 6 of 2015
 
National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1)
National Health Act 1953
I, ANDREW RINTOUL, Assistant Secretary (Acting), Pharmaceutical Evaluation Branch, Pharmaceutical Benefits Division, Department of Health, delegate of the Minister for Health, make this determination under subsection 85AB(1) of the National Health Act 1953.
Dated                23         January 2015
 
 
 
 
 
 
 
 
 
ANDREW RINTOUL
 
Assistant Secretary (Acting)
Pharmaceutical Evaluation Branch
Pharmaceutical Benefits Division
Department of Health
 
 
 
 
Part 1         Preliminary
1              Name of Determination
         (1)   This Determination is the National Health (Listed drugs on F1 or F2) Amendment Determination 2015 (No. 1).
         (2)   This Determination may also be cited as PB 6 of 2015.
2              Commencement
                This Determination commences on 1 February 2015.
3              Amendment of National Health (Listed drugs on F1 or F2) Determination 2010
                Schedule 1 amends the National Health (Listed drugs on F1 or F2) Determination 2010 (PB 93 of 2010).
Schedule 1             Amendments
 
(Section 3)
 
 
[1]     Schedule 1, after item dealing with Ciclesonide
 
Omit
 
Cidofovir
 
[2]     Schedule 2, after item dealing with Doxorubicin
 
Omit
 
Doxorubicin – Peglyated Liposomal
 
Insert
 
Doxorubicin – Pegylated Liposomal
 
[3]     Schedule 2, after item dealing with Duloxetine
 
Omit
 
Electrolyte replacement (oral)
 
Insert
 
Electrolyte Replacement, Oral
 
 
[4]     Schedule 2, after item dealing with Thyroxine
 
Omit
 
Ticlopidine